Literature DB >> 2790964

Human T cell responses to the Epstein-Barr nuclear antigen-1 (EBNA-1) as evaluated by synthetic peptides.

J Petersen1, G Rhodes, K Patrick, J Roudier, J H Vaughan.   

Abstract

A panel of synthetic peptides derived from Epstein-Barr virus (EBV) nuclear antigen 1 (EB-NA-1) was used to examine human T cell responses to this antigen. In six of seven normal persons with past EBV infection, T cell precursors specific for five peptides (P27, amino acid residues 83-101;P62, 148-166;E31, 353-367;E41, 368-381; and E11, 461-474) were detectable. The precursor frequencies were in the range of 1:20,000 to less than 1:100,000 peripheral blood mononuclear cells as determined by limiting dilution analyses. Only two of these peptides were predicted as alpha-helices; all peptides were glycine-rich. Four other peptides were not reactive in the seven individuals tested. T cell responses were not detectable in donors without prior EBV infection. Infectious mononucleosis patients investigated 4-6 weeks after diagnosis had likewise no detectable peptide-specific T cell precursors. Thus, it appears that T cells recognizing peptides from EBNA-1 arise and persist in people with past EBV infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790964     DOI: 10.1016/0008-8749(89)90293-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Epstein-Barr virus-induced autoimmune responses. II. Immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes. Presence in autoimmune disease.

Authors:  J H Vaughan; M D Nguyen; J R Valbracht; K Patrick; G H Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

3.  EBV-Associated Cancer and Autoimmunity: Searching for Therapies.

Authors:  Giovanni Capone; Candida Fasano; Guglielmo Lucchese; Michele Calabrò; Darja Kanduc
Journal:  Vaccines (Basel)       Date:  2015-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.